Cargando…
Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results
Respiratory syncytial virus (RSV) infection is the leading cause of infant hospitalizations and mortality. Lumicitabine, an oral nucleoside analog was studied for the treatment of RSV. The phase 1b and phase 2b studies reported here assessed the safety, pharmacokinetics, and pharmacodynamics of lumi...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355467/ https://www.ncbi.nlm.nih.gov/pubmed/37467213 http://dx.doi.org/10.1371/journal.pone.0288271 |
_version_ | 1785075149018497024 |
---|---|
author | Oey, Abbie McClure, Matthew Symons, Julian A. Chanda, Sushmita Fry, John Smith, Patrick F. Luciani, Kathia Fayon, Michael Chokephaibulkit, Kulkanya Uppala, Rattapon Bernatoniene, Jolanta Furuno, Kenji Stanley, Thorsten Huntjens, Dymphy Witek, James |
author_facet | Oey, Abbie McClure, Matthew Symons, Julian A. Chanda, Sushmita Fry, John Smith, Patrick F. Luciani, Kathia Fayon, Michael Chokephaibulkit, Kulkanya Uppala, Rattapon Bernatoniene, Jolanta Furuno, Kenji Stanley, Thorsten Huntjens, Dymphy Witek, James |
author_sort | Oey, Abbie |
collection | PubMed |
description | Respiratory syncytial virus (RSV) infection is the leading cause of infant hospitalizations and mortality. Lumicitabine, an oral nucleoside analog was studied for the treatment of RSV. The phase 1b and phase 2b studies reported here assessed the safety, pharmacokinetics, and pharmacodynamics of lumicitabine in infants/neonates hospitalized with RSV. In the phase 1b study, infants (≥1 to ≤12 months) and neonates (<28 days) received a single-ascending or multiple-ascending doses (single loading dose [LD] then 9 maintenance doses [MD] of lumicitabine, or placebo [3:1]). In the phase 2b study, infants/children (28 days to ≤36 months old) received lumicitabine 40/20 mg/kg, 60/40 mg/kg LD/MD twice-daily or placebo (1:1:1) for 5 days. Safety, pharmacokinetics, and efficacy parameters were assessed over 28 days. Lumicitabine was associated with a dose-related increase in the incidence and severity of reversible neutropenia. Plasma levels of ALS-008112, the active nucleoside analog, were dose-proportional with comparable mean exposure levels at the highest doses in both studies. There were no significant differences between the lumicitabine groups and placebo in reducing viral load, time to viral non-detectability, and symptom resolution. No emergent resistance-associated substitutions were observed at the RSV L-gene positions of interest. In summary, lumicitabine was associated with a dose-related increase in the incidence and severity of reversible neutropenia and failed to demonstrate antiviral activity in RSV-infected hospitalized infants. This contrasts with the findings of the previous RSV-A adult challenge study where significant antiviral activity was noted, without incidence of neutropenia. Trial registration ClinicalTrials.gov Identifier: NCT02202356 (phase 1b); NCT03333317 (phase 2b). |
format | Online Article Text |
id | pubmed-10355467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-103554672023-07-20 Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results Oey, Abbie McClure, Matthew Symons, Julian A. Chanda, Sushmita Fry, John Smith, Patrick F. Luciani, Kathia Fayon, Michael Chokephaibulkit, Kulkanya Uppala, Rattapon Bernatoniene, Jolanta Furuno, Kenji Stanley, Thorsten Huntjens, Dymphy Witek, James PLoS One Research Article Respiratory syncytial virus (RSV) infection is the leading cause of infant hospitalizations and mortality. Lumicitabine, an oral nucleoside analog was studied for the treatment of RSV. The phase 1b and phase 2b studies reported here assessed the safety, pharmacokinetics, and pharmacodynamics of lumicitabine in infants/neonates hospitalized with RSV. In the phase 1b study, infants (≥1 to ≤12 months) and neonates (<28 days) received a single-ascending or multiple-ascending doses (single loading dose [LD] then 9 maintenance doses [MD] of lumicitabine, or placebo [3:1]). In the phase 2b study, infants/children (28 days to ≤36 months old) received lumicitabine 40/20 mg/kg, 60/40 mg/kg LD/MD twice-daily or placebo (1:1:1) for 5 days. Safety, pharmacokinetics, and efficacy parameters were assessed over 28 days. Lumicitabine was associated with a dose-related increase in the incidence and severity of reversible neutropenia. Plasma levels of ALS-008112, the active nucleoside analog, were dose-proportional with comparable mean exposure levels at the highest doses in both studies. There were no significant differences between the lumicitabine groups and placebo in reducing viral load, time to viral non-detectability, and symptom resolution. No emergent resistance-associated substitutions were observed at the RSV L-gene positions of interest. In summary, lumicitabine was associated with a dose-related increase in the incidence and severity of reversible neutropenia and failed to demonstrate antiviral activity in RSV-infected hospitalized infants. This contrasts with the findings of the previous RSV-A adult challenge study where significant antiviral activity was noted, without incidence of neutropenia. Trial registration ClinicalTrials.gov Identifier: NCT02202356 (phase 1b); NCT03333317 (phase 2b). Public Library of Science 2023-07-19 /pmc/articles/PMC10355467/ /pubmed/37467213 http://dx.doi.org/10.1371/journal.pone.0288271 Text en © 2023 Oey et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Oey, Abbie McClure, Matthew Symons, Julian A. Chanda, Sushmita Fry, John Smith, Patrick F. Luciani, Kathia Fayon, Michael Chokephaibulkit, Kulkanya Uppala, Rattapon Bernatoniene, Jolanta Furuno, Kenji Stanley, Thorsten Huntjens, Dymphy Witek, James Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results |
title | Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results |
title_full | Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results |
title_fullStr | Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results |
title_full_unstemmed | Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results |
title_short | Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results |
title_sort | lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (rsv) infection: safety, efficacy, and pharmacokinetic results |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355467/ https://www.ncbi.nlm.nih.gov/pubmed/37467213 http://dx.doi.org/10.1371/journal.pone.0288271 |
work_keys_str_mv | AT oeyabbie lumicitabineanorallyadministerednucleosideanalogininfantshospitalizedwithrespiratorysyncytialvirusrsvinfectionsafetyefficacyandpharmacokineticresults AT mcclurematthew lumicitabineanorallyadministerednucleosideanalogininfantshospitalizedwithrespiratorysyncytialvirusrsvinfectionsafetyefficacyandpharmacokineticresults AT symonsjuliana lumicitabineanorallyadministerednucleosideanalogininfantshospitalizedwithrespiratorysyncytialvirusrsvinfectionsafetyefficacyandpharmacokineticresults AT chandasushmita lumicitabineanorallyadministerednucleosideanalogininfantshospitalizedwithrespiratorysyncytialvirusrsvinfectionsafetyefficacyandpharmacokineticresults AT fryjohn lumicitabineanorallyadministerednucleosideanalogininfantshospitalizedwithrespiratorysyncytialvirusrsvinfectionsafetyefficacyandpharmacokineticresults AT smithpatrickf lumicitabineanorallyadministerednucleosideanalogininfantshospitalizedwithrespiratorysyncytialvirusrsvinfectionsafetyefficacyandpharmacokineticresults AT lucianikathia lumicitabineanorallyadministerednucleosideanalogininfantshospitalizedwithrespiratorysyncytialvirusrsvinfectionsafetyefficacyandpharmacokineticresults AT fayonmichael lumicitabineanorallyadministerednucleosideanalogininfantshospitalizedwithrespiratorysyncytialvirusrsvinfectionsafetyefficacyandpharmacokineticresults AT chokephaibulkitkulkanya lumicitabineanorallyadministerednucleosideanalogininfantshospitalizedwithrespiratorysyncytialvirusrsvinfectionsafetyefficacyandpharmacokineticresults AT uppalarattapon lumicitabineanorallyadministerednucleosideanalogininfantshospitalizedwithrespiratorysyncytialvirusrsvinfectionsafetyefficacyandpharmacokineticresults AT bernatonienejolanta lumicitabineanorallyadministerednucleosideanalogininfantshospitalizedwithrespiratorysyncytialvirusrsvinfectionsafetyefficacyandpharmacokineticresults AT furunokenji lumicitabineanorallyadministerednucleosideanalogininfantshospitalizedwithrespiratorysyncytialvirusrsvinfectionsafetyefficacyandpharmacokineticresults AT stanleythorsten lumicitabineanorallyadministerednucleosideanalogininfantshospitalizedwithrespiratorysyncytialvirusrsvinfectionsafetyefficacyandpharmacokineticresults AT huntjensdymphy lumicitabineanorallyadministerednucleosideanalogininfantshospitalizedwithrespiratorysyncytialvirusrsvinfectionsafetyefficacyandpharmacokineticresults AT witekjames lumicitabineanorallyadministerednucleosideanalogininfantshospitalizedwithrespiratorysyncytialvirusrsvinfectionsafetyefficacyandpharmacokineticresults AT lumicitabineanorallyadministerednucleosideanalogininfantshospitalizedwithrespiratorysyncytialvirusrsvinfectionsafetyefficacyandpharmacokineticresults |